Zeiss Meditec cuts up to 1,000 jobs – what this means for Oberkochen

Carl Zeiss Meditec plans to cut up to 1,000 jobs worldwide over the next three years and relocate parts of its production to lower-cost countries. For the Oberkochen site, much remains uncertain for now: According to the company, it has not yet been decided which areas will be specifically affected. Questions regarding locations will only be clarified in upcoming discussions with employee representatives.

For the region, this is a central uncertainty. Around 1,100 employees work for Carl Zeiss Meditec in Oberkochen. The company, a subsidiary of the technology group Zeiss, manufactures, among other things, lasers, surgical microscopes, medical devices, and artificial lenses for the treatment of eye diseases. Accordingly, the question of whether and to what extent Oberkochen will be affected by the program depends not only on job numbers but also on the role of the site within the production and development network.

China business as the economic trigger – and as justification for tough targets

Zeiss Meditec justifies the cost-cutting measures with ongoing difficulties in its China business. This is more than a general description of the situation, as the group links the measures to a clearly quantified earnings target: By the 2028/29 fiscal year, results are to improve by more than 200 million euros annually compared to the current reporting period.

This makes the job cuts part of a broader cost and structural agenda. In practice, such programs aim to permanently reduce the cost base – often through personnel costs, but also through production depth, site configurations, and procurement. For employees and municipalities, the decisive factor is which levers the company actually pulls: Whether it is mainly about administrative functions, production areas, or a reorganization of value creation stages remains speculation until concrete site decisions are made.

Production relocation: Cost advantages – but also risks that can determine the fate of a site

The fact that Zeiss Meditec wants to relocate parts of its production to countries with lower costs may seem economically attractive in the short term: lower wages, lower operating costs, or more favorable conditions promise savings. In reality, however, the success of such steps often depends on factors that are quickly overlooked in public debate: start-up and relocation costs, the effort required for qualification and quality assurance, possible interruptions in supply chains, and the question of how sensitive products and processes are to the loss of know-how.

For Oberkochen, this means two things. First, the pressure increases on areas that can in principle be mapped flexibly in terms of location – such as standardized production steps where cost differences are particularly significant. Second, especially in highly precise medical technology applications, the counterargument can carry significant weight: When quality assurance, regulatory requirements, and process stability are particularly critical, relocation is not automatically the cheaper solution once all follow-up costs are taken into account. Whether Oberkochen is seen more as a cost factor or as a stability anchor in the production network is therefore likely to be a key question in the coming months.

Co-determination and negotiations: Why “no decision yet” is more than just a phrase

The fact that the company wants to make site decisions “in coordination with employee representatives” points to a process that takes time and can change outcomes. Especially when it comes to interventions in personnel structures, work organization, or far-reaching site measures, co-determination rights and negotiations with the works council are a relevant factor. For the workforce, this means: The announced framework is set, but the concrete details – which functions remain, which move, which are cut – are typically the subject of negotiations on implementation, timetable, and social security.

What is already certain – and what will be decisive for Oberkochen

So far, the global scope has been confirmed: up to 1,000 fewer jobs worldwide, partial relocation of production, and an earnings target of more than 200 million euros annual improvement by 2028/29.

For Oberkochen, the key question is what role the site will play in the production network in the future – and whether the company sees functions there that are difficult to relocate due to technical requirements, quality risks, or proximity to development and expertise. As long as Zeiss Meditec does not announce site-specific decisions, the most important finding for employees and the region remains: The restructuring has been announced, but the concrete local consequences have not yet been quantified.